https://www.hcplive.com/view/deucrictibant-xr-meets-primary-endpoint-hae-prophylaxis
Deucrictibant XR Meets Primary Endpoint in HAE Prophylaxis | HCPLive
Oct 14, 2026 - Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.
primary endpointdeucrictibantmeetshaeprophylaxis